Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

34.18 +1.10 (+3.33%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	518,462
Open	32.84
Bid (Size)	32.85 (300)
Ask (Size)	34.90 (200)
Prev. Close	33.08
Today's Range	32.84 - 34.60
52wk Range	8.300 - 40.22
Shares Outstanding	44,188,534
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates

April 30, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

April 07, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Performance

YTD	+10.6%	+10.6%
1 Month	+4.4%	+4.4%
3 Month	+11.1%	+11.1%
6 Month	+31.0%	+31.0%
1 Year	+254.9%	+254.9%

More News

Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares ↗

March 27, 2026

Via The Motley Fool

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

Via MarketMinute

Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally ↗

March 24, 2026

Via The Motley Fool

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 17, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 04, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 04, 2026

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

Via The Motley Fool

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

Via The Motley Fool

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Via The Motley Fool

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Via The Motley Fool

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 18, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

February 11, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 16, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Top movers in Monday's pre-market session ↗

January 12, 2026

Via Chartmill

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

January 11, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 16, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗

December 10, 2025

Via The Motley Fool

Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗

December 09, 2025

Via Chartmill

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Stoke Therapeutics, Inc. - Common Stock publicly traded?

Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?

Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?

The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market

What is the current price of Stoke Therapeutics, Inc. - Common Stock?

The current price of Stoke Therapeutics, Inc. - Common Stock is 34.18

When was Stoke Therapeutics, Inc. - Common Stock last traded?

The last trade of Stoke Therapeutics, Inc. - Common Stock was at 05/04/26 04:00 PM ET

What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?

The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.51B

How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?

Stoke Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.